|
|
| |
|
| |
|
 |
|
| |
Redaktion: Ricardo Munoz, Carol G. Schmitt, Stephen J. Roth, Eduardo da Cruz
Handbook of Pediatric Cardiovascular Drugs
erschienen Dezember 2007
356 Seiten, 13 schw.-w. Abb., 13 schw.-w. Zeichn., 25 schw.-w. Tabellen, Paperback
Springer-Verlag GmbH | ISBN: 1846289521
| |  | 64.15 EUR |  | | |
|
|
|
|
| |
Innerhalb 24 Stunden versandfertig. Expressversand: In Deutschland versandkostenfrei | Österreich: 4 € | Schweiz: ab 4 € | Europaweit ab 6 €. Versandkostenübersicht weltweit. Alle Preise inkl. MwSt. |
|
|
Ähnliche Bücher anzeigen
|
|
|
| |
| |
| VORWORT | öffnen |
|
PrefaceOur main purpose in editing this book is to provide the health care practitioner with general clinical practical guidelines regarding the use of pediatric cardiovascular drugs. We also intend to provide an overview of basic pediatric cardiovascular principles. We realize the need for a pocket reference handbook that is tailored to meet the daily challenges of practitioners that care for pediatric cardiac patients. This book is not intended to provide an extensive review of all cardiovascu...
[weiter lesen]
|
|
|
| KLAPPENTEXT | öffnen |
|
Munoz • Schmitt • Roth • da Cruz • Eds. Handbook of Pediatric Cardiovascular Drugs The treatment of pediatric patients with congenital or acquired cardiac disease remains an important challenge for physicians in charge of these patients.The challenge to practitioners is complex given that most drugs used in this field are either unlicensed or off-label and that the patient population is a heterogeneous group not only in pathologies but also in size, weight, and metabolism. Currently, docto... [weiter lesen] |
|
|
| AUTOR | öffnen |
|
ContributorsDonald Berry, BSPharm Pharmacy Department Children's Hospital of Pittsburgh Pittsburgh, PA, USA Constantinos Chrysostomou, MD Department of Pediatrics and Critical Care Children's Hospital of Pittsburgh University of Pittsburgh Medical Center Pittsburgh, PA, USA Eduardo da Cruz, MD Director of the Cardiac Intensive Care Unit Associate Professor of Pediatrics (Pediatric Cardiology & Intensive Care) The Heart Institute Department of Pediatrics The Children's Hospital of Denv... [weiter lesen] |
|
|
| INHALTSVERZEICHNIS | öffnen |
Contents
Foreword by Maurice Beghettiv
Prefacevii
Contributorsxi
1 Cardiac Physiology Review 1
Brian Feingold and Ricardo Munoz
2 Clinical Pharmacokinetics: Applications in Pediatric Practice 17
Denise L. Howrie and Carol G. Schmitt
3 Inotropic and Vasoactive Drugs 33
Eduardo da Cruz and Peter C. Rimensberger
4 Vasodilators 77
Stephen J. Roth, Ricardo Munoz, Carol G. Schmitt, Eduardo da Cruz, Jonatha...
5 Diuretic Medications 120
Donald Berry and Traci M. Kazmerski
6β-Blockers 139
Constantinos Chrysostomou and Traci M. Kazmerski
7 Antiarrhythmic Medications 150
Anne M. Dubin
8 Immunosuppressive Agents in Pediatric Heart Transplantation 190
Indira A. Khimji, Traci M. Kazmerski, and Steven A. Webber
9 Extracorporeal Membrane Oxygenation and Drug Clearance 215
Peter D. Wearden, Victor O. Morell, and Ricardo Munoz
10 Pharmacological Treatment of Pulmonary Hypertension 226
Mary P. Mullen and David L. Wessel
11 Anticoagulants, Antithrombotics, and Antiplatelets 248
Phuong-Tan Nguyen, Jessica Erin Sandy, and Ricardo Munoz
12 Sedative Hypnotic and Anesthetic Agents: Their Effect on the Heart 280
Charles I. Yang, Pravin Taneja, and Peter J. Davis
13 Drug Therapy for Hypercholesterolemia and Dyslipidemia 318
Sarah D. de Ferranti
14 Medication Errors in Children 334
Robert L. Poole
Index 343
[weiter lesen] |
|
|
|
|
| REGISTER | öffnen |
Index
AAbsorption, drug
- bioavailability and, 18
- critical care settings and, 29
- oral, 17
- percutaneous, 17-18
- rectal, 18
ACE inhibitors
advantages/disadvantages of, 227
- bumetanide and, 123
- Captopril, 78-81
- CHF and, 28-29
- CYP drug interactions and, 23
- enalapril, 78, 81-84
- hydrochlorothiazide and, 130
- lisinopril, 78, 85-88
- liver disease and, 26
- pulmonary hypertension and, 238
- renal disease and, 28
- spironolactone and, 133
Acetaminophen
- fenoldopam and, 113
- renal disease and, 27
Acetazolamide
- drug interactions/diluents, 136
- indication, 134
- mechanism/dosing/pharmacokinetics, 135
- warnings, 135-136
Action potential, 1, 2-3
Adalat CC. See Nifedipine Adenosine, 182-184
Administration. See specific drug
Adrenaline. See Epinephrine a-adrenergic agonists/blocking
agents, 43
Adrenergic agonist agents
- dobutamine, 40-41
- dopamine, 41-44
- norepinephrine, 50-52
- β-adrenergic agonists, 43
- β-adrenergic blocking agents dobutamine and, 40
- dopamine and, 43
- isoproterenol and, 49
Adrenoceptor antagonists
- phenoxybenzamine, 78, 107-109
- phentolamine, 78, 110-112
ADRs. See Adverse drug reactions
Adverse drug reactions (ADRs)
- challenges regarding, 339-340
- definitions of, 339
- drug classes associated with/types of, 340
- statistics on, 338
Adverse effects. See specific drug Afeditab. See Nifedipine
Afterload
- cardiac physiology and, 3, 5, 6-7
- pressure-volume loops and, 8, 9-10
- α-agonists, 30
- β-agonists, 227
Alcohols
- percutaneous absorption and, 17-18
- vasopressin and, 57
Alemtuzumab, 208-210
Allopurinol
- chlorothiazide and, 129
- metolazone and, 131
- renal disease and, 27
Alteplase, 248-250
Amiloride, 133-134
Aminocaproic acid, 251-252
Aminoglycosides
- bumetanide and, 123
- critical care settings and, 29
- drug distribution and, 19
- ethacrynic acid and, 127
- furosemide and, 121
- renal excretion and, 25
- torsemide and, 125
Amiodarone
- CHF and, 29
- CYP drug interactions and, 23, 25
- diluents, 173
Amiodarone (Continued) drug interactions, 172
- indication, 170
- losartanand, 91
- mechanism/dosing/pharmacokinetics/ monitoring, 171
- warnings, 172-173
Amlodipine (Norvasc)
- diluents/concentrations, 97
- dosing/pharmacokinetics/monitoring parameters, 95
- indication, 94
- liver disease and, 26-27
- mechanism of action, 78, 94-95
- warnings/drug interactions, 96
Amrinone. See Inamrinone/amrinone
Anaphylactic reactions/shock, 46
Anesthetic agents
- dexmedetomidine, 294-300
- dobutamine and, 40
- etomidate, 284-288
- fentanyl, 303-306
- halothane/isoflurane/sevoflurane/ desflurane, 310-314- ketamine, 289-294
- metaraminol and, 61
- midazolam, 307-310
- propofol, 280-284
- remifentanil, 300-303
Angiotensin II receptor blockers, 78, 88-91
- α-antagonists, 227
Antiarrhythmic medications
- action potential and, 2- adenosine, 182-184
- atropine, 184-185
- CHF and, 29
- class IA, 150-155
- disopyramide, 154-155
- procainamide, 152-154
- quinidine, 150-152
- class IB, 155-160
- lidocaine, 156-157
- mexiletine, 157-158
- Phenytoin, 158-160
- class IC, 160-163- flecainide, 160-161
- propafenone, 161-163- class II (ß-blockers), 163-170
- atenolol, 166-167- esmolol, 163-164- metoprolol, 167-169- nadolol, 169-170
- propranolol, 164-166
- class III, 170-179
amiodarone, 170-173
- bretylium, 176-177
- ibutilide, 177-179
- Sotalol, 173-176
- class IV (calcium channel blockers), 179-182
- diltiazem, 181-182
- verapamil, 179-181
- CYP drug interactions and, 24
- digoxin, 35-39
- magnesium sulfate, 185-187
Antibiotics, 340
Antibodies to IL 2 R and, 190
- basiliximab, 210-212
- daclizumab, 212-213
Anticoagulants
alteplase, 248-250
aminocaproic acid, 251-252
aprotinin, 252-255
argatroban, 255-257
aspirin, 257-260
- Clopidogrel, 260-262
- dipyridamole, 262-264
- enoxaparin, 264-267
- heparin, 267-269
- lepirudin, 269-272
- liothyronine and, 66
- protamine, 272-274
- spironolactone and, 133
- tranexamic acid, 274-275
- warfarin, 275-278
Anticoagulation, 238
Anticonvulsants, 340
Antidepressants, 30
Antifungal agents, 340
Antimetabolites
AZA, 190, 191, 198-200
- mycophenolate mofetil, 190, 191, 200-202
Antineoplastic agents, 340
Antiplatelets. See Anticoagulants
Antithrombotics. See Anticoagulants
Aprotinin, 252-255
Argatroban, 255-257
Aspirin, 257-260
Atenolol
- calcium chloride and, 64
- as class II antiarrhythmic, 166-167
- renal disease and, 28
Atgam. See Equine antithymocyte globulin
Atorvastatin
- CYP drug interactions and, 24
- lipid lowering and, 322-325
Atrial natriuretic peptide, 236
Atrioventricular (AV) node, 1, 2
Atropine
- as antiarrhythmic, 184-185
- metaraminol and, 61
Atropine-resistant bradycardia, 46
Automaticity, 3-4
AV. See Atrioventricular node
AZA. See Azathioprine
Azathioprine (AZA), 190, 191, 198-200
Azole antifungals
amlodipine and, 96
- CYP drug interactions and, 23, 24
- nicardipine and, 100
BBasic cardiac structure/function, 1
Basiliximab, 210-212
Benzodiazepines
- digoxin interactions with, 38
- drug distribution and, 19
Bergamottin, 24
Bile acid sequestrants, 319-322
- β-blockers, 163-170
- atenolol, 166-167
- Carvedilol, 142-145
- CYP isoenzymes and, 20-22
- epinephrine and, 47
- esmolol, 147, 163-164
[weiter lesen] |
|
|
|
|
|
|